Pharmaceutical

AAO 2024: NMA reveals Vabysmo’s superior CST improvement over Eylea HD

This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.  

Oct 24, 2024 - 04:00
AAO 2024: NMA reveals Vabysmo’s superior CST improvement over Eylea HD
This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.  
Read the original article

Tags:

Previous Article

FDA approves Alvotech and Teva’s SELARSDI for new indications

Next Article

Health Canada approves Servier’s VORANIGO for IDH-mutant glioma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Evotec partners with Crohn’s & Colitis Foundation for IBD therapies

Evotec partners with Crohn’s & Colitis Foundation for I...

Jan 11, 2024

STAT+: Brigham and Women’s exec opens up about the Dana-Farber Cancer Institute split, and what it means for the future of cancer care

STAT+: Brigham and Women’s exec opens up about the Dana...

Sep 28, 2023

3 issues to watch in global health in 2024

3 issues to watch in global health in 2024

Dec 23, 2023